164 related articles for article (PubMed ID: 8242612)
21. Alterations in signal transducing molecule CD3 zeta in patients with neoplastic diseases.
Frydecka I; Kaczmarek P; Boćko D; Kosmaczewska A; Ciszak L
Arch Immunol Ther Exp (Warsz); 1998; 46(6):355-9. PubMed ID: 9883314
[TBL] [Abstract][Full Text] [Related]
22. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
Cancer Res; 1999 Jun; 59(12):2950-6. PubMed ID: 10383160
[TBL] [Abstract][Full Text] [Related]
23. Fc epsilonRI gamma can support T cell development and function in mice lacking endogenous TCR zeta-chain.
Shores E; Flamand V; Tran T; Grinberg A; Kinet JP; Love PE
J Immunol; 1997 Jul; 159(1):222-30. PubMed ID: 9200458
[TBL] [Abstract][Full Text] [Related]
24. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM; Rayman P; Uzzo R; Bloom T; Sandstrom K; Peereboom D; Olencki T; Budd GT; McLain D; Elson P; Novick A; Finke JH
Clin Cancer Res; 1998 Oct; 4(10):2337-47. PubMed ID: 9796963
[TBL] [Abstract][Full Text] [Related]
25. T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma.
Cardi G; Heaney JA; Schned AR; Phillips DM; Branda MT; Ernstoff MS
Cancer Res; 1997 Aug; 57(16):3517-9. PubMed ID: 9270022
[TBL] [Abstract][Full Text] [Related]
26. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus.
Nambiar MP; Fisher CU; Warke VG; Krishnan S; Mitchell JP; Delaney N; Tsokos GC
Arthritis Rheum; 2003 Jul; 48(7):1948-55. PubMed ID: 12847689
[TBL] [Abstract][Full Text] [Related]
27. Lactoferrin-induced up-regulation of zeta (zeta) chain expression in peripheral blood T lymphocytes from cervical cancer patients.
Frydecka I; Zimecki M; Bocko D; Kosmaczewska A; Teodorowska R; Ciszak L; Kruzel M; Wlodarska-Polinsk J; Kuliczkowski K; Kornafel J
Anticancer Res; 2002; 22(3):1897-901. PubMed ID: 12168890
[TBL] [Abstract][Full Text] [Related]
28. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
Moritz D; Groner B
Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
[TBL] [Abstract][Full Text] [Related]
29. Absent or low expression of T-cell receptor zeta-chain in T cells infiltrating human pathological skin conditions.
Alaibac M; Pigozzi B; Saponeri A; Belloni-Fortina A; Peserico A
Arch Dermatol Res; 2002 Nov; 294(8):380-2. PubMed ID: 12420108
[TBL] [Abstract][Full Text] [Related]
30. Chronic inflammation and CD16+ natural killer cell zeta-chain downregulation in hemodialysis patients.
Eleftheriadis T; Kartsios C; Yiannaki E; Kazila P; Antoniadi G; Liakopoulos V; Markala D
Blood Purif; 2008; 26(4):317-21. PubMed ID: 18463433
[TBL] [Abstract][Full Text] [Related]
31. Sequential development of structural and functional alterations in T cells from tumor-bearing mice.
Correa MR; Ochoa AC; Ghosh P; Mizoguchi H; Harvey L; Longo DL
J Immunol; 1997 Jun; 158(11):5292-6. PubMed ID: 9164948
[TBL] [Abstract][Full Text] [Related]
32. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
Carrega P; Morandi B; Costa R; Frumento G; Forte G; Altavilla G; Ratto GB; Mingari MC; Moretta L; Ferlazzo G
Cancer; 2008 Feb; 112(4):863-75. PubMed ID: 18203207
[TBL] [Abstract][Full Text] [Related]
33. Selective binding of shc-SH2 domain to tyrosine-phosphorylated zeta but not gamma-chain upon CD16 ligation on human NK cells.
Galandrini R; Palmieri G; Paolini R; Piccoli M; Frati L; Santoni A
J Immunol; 1997 Oct; 159(8):3767-73. PubMed ID: 9378963
[TBL] [Abstract][Full Text] [Related]
34. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.
Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
Anticancer Res; 2000; 20(2B):1093-100. PubMed ID: 10810402
[TBL] [Abstract][Full Text] [Related]
35. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors.
Taylor DD; Gerçel-Taylor C; Lyons KS; Stanson J; Whiteside TL
Clin Cancer Res; 2003 Nov; 9(14):5113-9. PubMed ID: 14613988
[TBL] [Abstract][Full Text] [Related]
36. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.
Lockhart DC; Chan AK; Mak S; Joo HG; Daust HA; Carritte A; Douville CC; Goedegebuure PS; Eberlein TJ
Surgery; 2001 Jun; 129(6):749-56. PubMed ID: 11391375
[TBL] [Abstract][Full Text] [Related]
37. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma.
Reichert TE; Day R; Wagner EM; Whiteside TL
Cancer Res; 1998 Dec; 58(23):5344-7. PubMed ID: 9850063
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
Schleypen JS; Baur N; Kammerer R; Nelson PJ; Rohrmann K; Gröne EF; Hohenfellner M; Haferkamp A; Pohla H; Schendel DJ; Falk CS; Noessner E
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):718-25. PubMed ID: 16467081
[TBL] [Abstract][Full Text] [Related]
39. NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.
Chambers WH; Bozik ME; Brissette-Storkus SC; Basse P; Redgate E; Watkins S; Boggs SS
Cancer Res; 1996 Aug; 56(15):3516-25. PubMed ID: 8758920
[TBL] [Abstract][Full Text] [Related]
40. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
